Kornimate/medical-research-clean huggingface dataset:
transversus abdominis plane block versus quadratus lumborum block in the pediatric population undergoing orchiopexy

Conditions: Pain, Postoperative

Summary: transversus abdominis plane (tap) and quadratus lumborum (ql) blocks are used for the management of acute pain treatment, especially after the lower and upper abdominal surgeries. the tap block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. however, in ql block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia. the investigators' aim in this study, to investigate the effect of the tap and ql blocks on peroperative and postoperative analgesic consumption in children undergoing unilateral elective orchiopexy.

american society of anesthesiologists physical status classification system (asa) class i-iii, aged 6 month-12 years old children undergoing unilateral elective orchiopexy with general anesthesia will be recruited, after the informed consent will be obtained from the parents of the patients, in this randomized controlled trial. after the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. after the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. the maintenance of the anesthesia will be provided with sevoflurane. subsequently, before the surgery, the patients will be randomized and separated into 2 groups. the investigators will apply the ql block to the first group and tap block to the other group. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both group. in the peroperative period, if the additional analgesia will necessary, remifentanyl 0.1mcg/kg/min will be started, and dosage will be adjusted according to heart rate and blood pressure. if the blood pressure or heart rate will increase more than 20% from the preoperative basal value will be defined as the need for the analgesia. in the postoperative period, all cohort will be assessed by a blinded investigator at the 10,20,30th minutes, 1,2nd hours in the recovery room, 6th hour in the surgical ward, face, legs, activity, cry, consolability scale (flacc) will be used for the pain evaluation. 16th and 24th hours will be monitored by the telephone visit from the parents, the pain will be evaluated with the wong-baker faces pain rating scale due to the same-day surgery concept.

Eligibility criteria:
inclusion criteria: * asa physical status i-iii * undergoing elective unilateral orchiopexy exclusion criteria: * not giving a consent * asa physical status iv * need to postoperative icu care * history of allergic reactions to anesthetics * infection at the injection site * laparoscopic orchiopexy

Keywords: quadratus lumborum block transversus abdominis plane block pediatric patient orchiopexy regional anesthesia pain
radiotherapy combined with s-1/ddp for elderly esophageal squamous cell cancer.

Conditions: Esophageal Squamous Cell Carcinoma

Summary: this prospective, single-arm phase ⅱ study is to determine the efficacy and safety of once-daily simultaneous modulated accelerated radiotherapy combined with s-1/ddp for geratic esophageal squamous cell carcinoma patients.


Eligibility criteria:
inclusion criteria: * pathologically or cytologically confirmed esophageal squamous cell carcinoma. * stage ii-iva escc confirmed by endoscopic ultrasonography(eus) and imaging studies. * aging from 70 to 80. * eastern cooperative oncology group (ecog) performance status 0-2. * charlson's weighted index of comorbidities (wic) ≤4； * white blood cell count ≥4×109 /l, neutrophile granulocyte count≥1.5×109 /l, platelet count≥100×109 /l, hemoglobin ≥100 g /l, serum creatinine and bilirubin 1.5 times less than the upper limits of normal (uln),aminotransferase two times less than the uln. * weight loss ≤15% within the past half year. * forced expiratory volume in 1 s≥ 1 l. * patients and their family signed the informed consents. exclusion criteria: * previous or recent another malignancy, except for nonmelanoma skin cancer or cervical cancer in situ. * already received antineoplastic therapy,including chemotherapy, radiotherapy or operation. * any contraindication for chemotherapy or radiotherapy(such as a myocardial infarction within 6 months,immunosuppressive therapy,symptomatic heart disease,including unstable angina pectoris, congestive heart failure,and uncontrolled arrhythmia.) * malignant pleural effusion or pericardial effusion. * weight loss \>10% within the past 3 months. * recruited in other clinical trials within 30 days * drug addiction, long-term alcohol abuse and aids patients. * uncontrollable epileptic attack or psychotic patients without self-control ability. * severe allergy or idiosyncrasy. * not suitable for this study judged by researchers.

Keywords: once-daily simultaneous modulated accelerated radiotherapy s-1 ddp elderly patients
cilengitide in recurrent and/or metastatic squamous cell carcinoma of the head and neck (scchn)

Conditions: Squamous Cell Cancer

Summary: the purpose of this open-label, randomized, controlled, phase 1/2 study of the integrin inhibitor cilengitide is to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-fluorouracil (5-fu), and cetuximab in participants with recurrent/metastatic squamous cell carcinoma of the head and neck (scchn). the phase 1 part was conducted in dedicated study centers. in the phase 2 part of this trial, cilengitide is administered at two different doses to two experimental groups. the third group will only receive cisplatin, 5-fu and cetuximab. in the phase 1 part of this trial, the dose of cilengitide in combination with cisplatin, 5-fu and cetuximab was determined. cilengitide is an experimental anti-cancer substance interacting with so-called integrins. integrins are protein molecules that are known to be present on the surface of certain cancer cells. integrins are also found on certain cells that belong to growing blood vessels (endothelial cells). integrins potentially facilitate the blood vessels' support of the tumor (angiogenesis) as well as the tumor's growth and further spread throughout the body (metastasis). by inhibiting integrins on the tumor cell surface, cilengitide potentially kills cancer cells, and potentially sensitizes cancer cells to other co-administered therapeutics. by inhibiting integrins on the endothelial cell surface, it potentially inhibits the ingrowth of additional blood vessels towards the tumor. cilengitide is given as an intravenous infusion (given by a drip in one vein of your arm). if any unacceptable side effect occurs, treatment with the study drug will be stopped.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of scchn * at least one measurable lesion either by computerized tomography (ct) scan or magnetic resonance imaging (mri) * karnofsky performance status (kps) of greater than or equal to 70 or eastern cooperative oncology group performance status (ecog ps) of 0-1 at trial entry exclusion criteria: * prior systemic chemotherapy, except if given as part of a multimodal treatment for locally advanced disease, which was completed more than 6 months prior to trial entry * surgery (excluding prior diagnostic biopsy) or irradiation within 4 weeks before trial entry * nasopharyngeal carcinoma * documented or symptomatic brain or leptomeningeal metastasis * previous treatment with epidermal growth factor receptor (egfr) targeting therapy or signal transduction inhibitors

Keywords: randomized treatment open-label controlled recurrent metastatic scchn suitable for local therapy
treatment of primary hyperoxaluria type 1 with nedosiran

Conditions: Primary Hyperoxaluria Type 1 (PH1)

Summary: the purpose of this program is to provide participants with access to an investigational drug, nedosiran, for treatment of primary hyperoxaluria type 1 (ph1). eligible participants may receive nedosiran in this program until the drug is commercially available or until novo nordisk terminates the program, whichever comes first. novo nordisk may terminate the program at any time for any reason, including if the drug receives regulatory approval and becomes commercially available, or if the drug does not receive regulatory approval. nedosiran will be given once a month with a thin needle in the thigh or abdomen. the study doctor will ask the participant to come to the clinic monthly. the study doctor may allow participant to take nedosiran at home for self-administration. the participant should let the doctor know if they are unable to make a visit so it can be rescheduled. participants to inform the study doctor of any medications they are taking, including over the counter medicines, vitamins, and herbal medicines. if any medications change in dose, or new medications are added, participants should inform the study doctor. study doctor should be informed of any new or continued health problems or any changes in the participant's health.


Eligibility criteria:
early access eligibility criteria: * written, signed, and dated informed patient/parent consent; and for patients who were minors, age-appropriate assent (performed according to local regulations) * male or female patients at least 2 years of age * genetically-confirmed diagnosis of ph1 * accessible for treatment and follow-up and be able to comply with treatment monitoring requirements * not eligible for an ongoing rnai therapy trial and not participating simultaneously in any interventional clinical research study * patients with ph1 that are not satisfactorily treated with current standard of care; i.e., 24-hour urinary oxalate (uox) excretion ≥ 0.7 (millimoles) mmol for participants 18 years and older, or greater or lesser than (≥) 0.7 mmol per 1.73 metre square (m\^2) body surface area (bsa) for participants less than 18 years of age * estimated gfr at screening ≥ 30 millilitres per minute (ml/min) normalized to 1.73 m\^2 bsa * no renal or hepatic transplantation; prior or planned within the treatment period * no documented evidence of clinical manifestations of systemic oxalosis (including pre existing retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations) * patient not currently on dialysis * plasma oxalate ≤ 30 micromoles per litre (μmol/l) * female patients not breastfeeding or pregnant * the potential benefit for the individual patient justifies the potential risks of treatment as per prescribing physician judgment
electrical nerve stimulation of the ulnar nerve

Conditions: Cubital Tunnel Syndrome

Summary: cubital tunnel syndrome is caused by compression of the ulnar nerve at the elbow. this leads to symptoms such as chronic hand weakness, numbness and pain. this is usually treated with a surgical procedure where the nerve is decompressed. research has shown that nerve simulators speed up the recovery of nerves following injury. the purpose of our research is to examine the difference in patient outcomes after the nerve decompression surgery with and without nerve stimulation. our research questions is: what are the differences in long term functional outcomes of patients that have ulnar nerve decompression surgery with and without nerve stimulation?

1. patients will be seen in university of chicago clinics, if they are diagnosed with cubital tunnel syndrome, they will be approached to be enrolled in our study 2. if they fit inclusion and exclusion criteria, failed conservative management, and consent to be part of the study, they will be scheduled for cubital tunnel surgery and randomized into intervention/non-intervention group 3. patients will have pre-operative subjective pain and upper extremity function surveys and objective hand strength/sensation measurements done by a blinded occupational therapist in university of chicago occupational therapy clinic. patient will also have a pre-operative emg done. 4. patient will be discharged following surgery and followed up at 6 weeks, 3 months, 6 months, 12 months. emg will be done at 3 months and the same outcome measurements (pain scores, prune evaluation, quickdash questionnaire, michigan hand questionnaire, grip strength, sensation measurements) will be taken at each postoperative visit by the same blinded occupational therapist 5. data will be compared pre and postoperatively

Eligibility criteria:
inclusion criteria * emg confirmed ulnar nerve neuropathy at cubital tunnel with or without these symptoms: * paresthesia or numbness of the small finger and/or ring finger * complaints of hand weakness * exam shows positive flexion compression test at elbow and/or positive tinel's sign at the cubital tunnel * failed conservative management for 6 weeks ○ has completed a combination of these for 6 weeks and still has symptoms * night splinting in 45-60 degrees of flexion and forearm neutral * padding of elbow with an elbow pad during the day * daily nsaids if able to take them * cubital tunnel steroid injection * age restriction: 18--65years old exclusion criteria * psychiatric conditions * workman's compensation patients * neurologic conditions (ex. ms) * inflammatory rheumatologic conditions (connective tissues disease, ra... etc) * associated elbow and upper extremity fractures * previous cubital tunnel surgeries * previous c-spine surgeries * pregnancy
treatment of anemia in the 2nd year of life. comparison of the efficacy of two different iron preparations.

Conditions: Iron Deficiency; Anemia

Summary: healthy toddlers (age 9-18 month) following a routine blood count will be placed in three groups: 1. iron deficiency with no anemia 2. anemia 3. no anemia and no iron deficiency following a nutritional questionnaire, parents of all toddlers will receive instruction regarding appropriate nutrition in the 2nd year of life. groups 1 and 2 will randomly receive one of two preparations currently in use for treatment of iron deficiency in israel (aktiron 35 - ferrous gluconate and ferripel-3 - iron polysaccharide complex). followup blood count will be taken 3 month after recruitment. the study aims to compare the effectiveness of the iron preparations regarding compliance and efficacy. the hypothesis is that a significant difference will be detected between the two preparations.


Eligibility criteria:
inclusion criteria: * healthy toddlers age 9-18 months exclusion criteria: * toddlers with: chronic diseases, prematurity, inherited hematological disease.
eeg (electroencephalogram) platform standardization in healthy male subjects (3134-010)

Conditions: Dementia

Summary: the objective of this study is to test the experimental reproducibility and within-subject variability of qeeg (quantitative electroencephalogram) using two probe compounds: mk3134 and lorazepam. this study will test the hypothesis that eeg (electroencephalogram) theta power, averaged across a topographical region of interest is decreased 6 hours after administration of mk3134 compared to placebo. the objective of this study is to test the experimental reproducibility and within-subject variability of qeeg using two probe compounds: mk3134 and lorazepam.


Eligibility criteria:
inclusion criteria: * subject is a male between 18 to 40 years of age * the subject has a body mass index (bmi) greater than or equal to 31 kg/m\^2 at the prestudy (screening) visit * subject has normal or corrected to normal visual and auditory acuity * subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months * subject is right-handed exclusion criteria: * subject has permanent cosmetic or metallic objects in their body that can interfere with the measurements * subject has a history of stroke, chronic seizures, or major neurological disorder * subject has a history of neoplastic disease * subject has a current diagnosis of or a prior history of sleep apnea * subject has a history of fainting during blood draws * subject has a history of significant head injury/trauma * subject has a current diagnosis of or history of bipolar illness, schizophrenia, attention deficit hyperactivity disorder (adhd), or claustrophobia * subject works a night shift and is not able to avoid night shift work within 3 days before each treatment visit * subject is currently a regular user of any illicit drugs or has a significant history of drug (including alcohol) abuse

Keywords: eeg standardization
prospective evaluation of the clinical utility of peroral endoscopic myotomy for gastrointestinal motility disorders

Conditions: Achalasia; Esophageal Spasm, Diffuse; Gastroparesis; Swallowing Disorder; Zenker Diverticulum

Summary: this is prospective data recording study. all patients will receive standard medical care and no experimental interventions will be performed.

this is prospective data recording study. all patients will receive standard medical care and no experimental interventions will be performed. this study will enroll 600 subjects over the next 4 to 5 years.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older. 2. scheduled to undergo poem exclusion criteria: 1. any contraindication to performing endoscopy. 2. participation in another research protocol that could interfere or influence the outcomes measures of the present study.
third molar: caries, periodontal desease and quality of life

Conditions: Caries; Periodontal Diseases

Summary: caries and periodontal disease are chronic diseases of the oral cavity. the incidence of caries and periodontal disease can vary depending on the position of the third molar, the aim of this study was to verify possible associations between oral health-related quality of life (qol), periodontal disease, caries lesions and the position of the lower third molar.

caries and periodontal disease are chronic diseases of the oral cavity. the presence of third molar teeth can lead to periodontal disease in the region, and often can lead to injuries and damage to the oral health, having a significant impact on the quality of life. the incidence of caries and periodontal disease can vary depending on the position of the third molar. purpose: the aim of this study was to verify possible associations between oral health-related quality of life (qol), periodontal disease, caries lesions and the position of the lower third molar. materials and methods: the investigators performed a clinical, observational cross-sectional study within 116 patients that were screened attending to evaluate the need for extraction of third molars at of the specialization course of oral and maxillofacial surgery of fundecto-ffo-usp. caries, periodontal disease and quality of life are the outcomes that were evaluated by the main researcher. caries lesions were assessed by visual tactile examination and periodontal disease through two probing sites around third molar, considering the presence of periodontal pathology when at least one periodontal probing depth was greater than 4 mm, and both were evaluated by radiograph diagnostic methods. the assessment of oral health related quality of life by oral health impact profile questionary (ohip-14), applied as an interview. the evaluation of the position of the third molars was made by clinical and panoramic radiographs according to the classification of pell and gregory and winter. data was treated and analyzed according to stata 13.0, software with descriptive and inferential statistics. the level of significance used was 95%. results: partially erupted and angulation of third molar increase the incidence of caries and periodontal disease in these teeth. symptoms and age are factors associated with caries and periodontal disease. patients with caries have higher scores in domains 3 and 6 and those with periodontal disease have higher scores in domains 3 and 4. pathologies on third molar region had impact on domain 7.

Eligibility criteria:
inclusion criteria: * asa i patients (negative medical history), with at least one third molar erupted or partially erupted. exclusion criteria: * systemically compromised * allergic * pregnants * patients who had the four third molars included * patients who have already undergone the extraction of one of the third molars

Keywords: molar third; dental caries periodontal disease quality of life
effect of montelukast on kidney and vascular function in type 1 diabetes

Conditions: Albuminuria

Summary: kidney disease is a common problem among people with type 1 diabetes and can lead to disability, dialysis, and early death. inflammation plays a key role in the development of kidney disease in type 1 diabetes and targeting leukotrienes, inflammatory chemicals the body releases in response to allergic reactions, may represent a promising therapy to slow the progression of diabetic kidney disease. the current proposal will investigate whether montelukast, a leukotriene blocker, lowers increased levels of protein in the urine (an early marker of diabetic kidney disease), and improves kidney and cardiovascular function in people with type 1 diabetes and kidney disease.


Eligibility criteria:
inclusion criteria: * age 18-80 years * type 1 diabetes for at least 5 years * urine albumin to creatinine ratio 30-5000 mg/g on first morning void * egfr 30-89 ml/min/1.73m2 at time of screening * blood pressure \<140/90 mm hg prior to randomization * use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker with stable dose for 4 weeks * bmi \< 40 kg/m2 (fmdba measurements can be inaccurate in severely obese patients). * stable anti-hypertensive regimen for at least one month prior to randomization * stable regimen of insulin delivery, i.e. automated insulin delivery (aid) system or multiple daily injections) 4 weeks prior to randomization * sedentary or recreationally active (≤2 days of vigorous aerobic exercise as vigorous exercise may affect vascular function measurements) * able to provide consent exclusion criteria: * significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year * uncontrolled hypertension * factors judged to limit adherence to interventions * anticipated initiation of dialysis or kidney transplantation within 6 months * current participation in another research study * pregnancy or planning to become pregnant or currently breastfeeding * allergy to aspirin * severe hepatic impairment (child-pugh class c) * history of major psychiatric disorder * use of inhaled or systemic corticosteroids or long-acting beta agonists (higher risk of neuropsychiatric reaction) * penicillin allergy * iodine allergy * shellfish allergy * current use of phenobarbital, rifampin or carbamazepine